Mark Denison
Last active: 2/22/2016

Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.

Dulek DE, Williams JV, Creech CB, Schulert AK, Frangoul HA, Domm J, Denison MR, Chappell JD
Clin Infect Dis. 2010 50 (11): 1493-6

PMID: 20415572 · DOI:10.1086/652655

Immunosuppressed patients receiving oseltamivir for 2009 novel H1N1 influenza A infection may develop drug resistance, leading to treatment failure. Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamivir-resistant novel H1N1 pneumonia. The regimen was well tolerated and was associated with a decrease in viral burden.

MeSH Terms (15)

Antiviral Agents Compassionate Use Trials Critical Illness Drug Resistance, Viral Female Humans Immunocompromised Host Infant Influenza, Human Influenza A Virus, H1N1 Subtype Injections, Intravenous Oseltamivir Treatment Outcome Viral Load Zanamivir

Connections (3)

This publication is referenced by other Labnodes entities:

Links